$7.87
3.32%
Nasdaq, Jan 02, 10:03 pm CET
ISIN
US21833P1030
Symbol
CRBP

Corbus Pharmaceuticals Holdings Inc Stock price

$7.87
-2.41 23.44% 1M
+0.12 1.55% 6M
-0.27 3.32% YTD
-4.17 34.63% 1Y
+4.56 137.41% 3Y
-30.23 79.34% 5Y
-40.43 83.71% 10Y
-82.14 91.26% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.27 3.32%
ISIN
US21833P1030
Symbol
CRBP
Industry

Key metrics

Basic
Market capitalization
$138.1m
Enterprise Value
$34.2m
Net debt
positive
Cash
$104.0m
Shares outstanding
12.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 67.7
EV/Sales
- | 16.7
EV/FCF
negative
P/B
1.5
Financial Health
Equity Ratio
91.4%
Return on Equity
-28.1%
ROCE
-82.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $2.0m
EBITDA
$-75.6m | -
EBIT
$-75.9m | $-87.8m
Net Income
$-67.5m | $-87.0m
Free Cash Flow
$-59.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-65.8% | -
EBIT
-64.3% | -79.2%
Net Income
-74.4% | -117.5%
Free Cash Flow
-61.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -4,263.7%
Free Cash Flow
-
More
EPS
$-5.5
FCF per Share
$-4.7
Short interest
8.5%
Employees
28
Rev per Employee
$0.0
Show more

Is Corbus Pharmaceuticals Holdings Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Corbus Pharmaceuticals Holdings Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Corbus Pharmaceuticals Holdings Inc forecast:

15x Buy
94%
1x Hold
6%

Analyst Opinions

16 Analysts have issued a Corbus Pharmaceuticals Holdings Inc forecast:

Buy
94%
Hold
6%

Financial data from Corbus Pharmaceuticals Holdings Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 15 15
2% 2%
-
- Research and Development Expense 60 60
99% 99%
-
-76 -76
66% 66%
-
- Depreciation and Amortization 0.32 0.32
47% 47%
-
EBIT (Operating Income) EBIT -76 -76
64% 64%
-
Net Profit -68 -68
74% 74%
-

In millions USD.

Don't miss a Thing! We will send you all news about Corbus Pharmaceuticals Holdings Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Corbus Pharmaceuticals Holdings Inc Stock News

Neutral
Seeking Alpha
23 days ago
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data Transcript
Positive
Schaeffers Research
24 days ago
Positive drug trial results are boosting pharmaceutical stocks today, with Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) and Eli Lilly & Co. (NYSE:LLY) drawing investor attention after encouraging developments for their latest obesity drugs.
Neutral
GlobeNewsWire
24 days ago
NORWOOD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the completion of the single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a study of CRB-913 and the initiation of a Phase 1b dose-range finding study ("CANYON-1"), with completion expected in summer 202...
More Corbus Pharmaceuticals Holdings Inc News

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.

Head office United States
CEO Yuval Cohen
Employees 28
Founded 2009
Website www.corbuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today